40. (TWICE AMENDED) A therapeutic composition comprising:

a therapeutically effective amount of a compound having the formula:



wherein:

each R1 and R2, independently, is H, C1-C12 alkyl, C6-C18 aryl, C1-C18 acyl, C7-C18 aralkyl, C7-C18 alkaryl or a dihydrotrigonellinate group;

A1 is a D or L-amino acid selected from the group consisting of Cys, Leu, Dap, Trp, Gln, a tethered amino acid with an indole ring, Phe, Hyp, a derivative of Trp selected from the group consisting of N-Me-Trp, nor Trp, beta Me-Trp, 2-Cl-Trp, and 5-X-Trp where X is selected from the group consisting of CN, Br, NH_2, COOH, CH_2NH_2 and CH_2-CH_2NH_2; CαMe-Trp, CαMe-Gln, Des-amino-Trp, Pyr, Bth, Nal, Tcc, Asn, Nva, Abu, Tyr, Tic-OH, Phe, Tip, and Dip;

A2 is a D or L-amino acid selected from the group consisting of Cys, Trp, Arg, Nα-Me-Arg, CαMe-Arg, Orn, Cit, hArg(R)2, where R is selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, or alkylaryl, Lys-ε-NH-R, where R is selected from the group consisting of alkyl, aryl, aralkyl, or alkylaryl; A3 is a D or L-amino acid selected from the group consisting of Glu, N-Me-Tyr, CαMe-Tyr, Tic-OH, Tic, Dip, Trp, Phe, des-carboxylic-Tyr (tyramine), and Tyr-(R), where R is hydrogen or a lipophilic group;

W is -OH, -N-R3R4, or OR5, where R3, R4, and R5 , independently, is H, C1-C12 alkyl, C6-C18 aryl, Cl-C12 acyl, C7-C18 aralkyl, or C7-C18 alkaryl, or a pharmaceutically acceptable salt thereof; and

each bond between two amino acids or amino acid derivatives, represented by a dash ("-"), can be either a peptide bond or a pseudopeptide bond; and

a pharmaceutically acceptable carrier substance;

said composition being capable of attenuating Neuropeptide Y (NPY) mediated or NPY-like physiological responses.

47. (AMENDED) The composition of claim 40, wherein said composition is in the form of a pill, tablet, or capsule for oral administration.

48. (AMENDED) The composition of claim 40, wherein said composition is in the form of a liquid for oral administration.

49. (AMENDED) The composition of claim 40, wherein said composition is in the form of a liquid for nasal administration as drops or spray.

50. (AMENDED) The composition of claim 40, wherein said composition is in the form of a liquid for intravenous, subcutaneous, parenteral, or intraperitoneal administration.

51. (AMENDED) The composition of claim 40, wherein said composition is in the form of a biodegradable sustained- release composition for intramuscular administration.

52. (AMENDED) The composition of claim 40, wherein said composition includes a lipophilic salt and is suitable for administration in the form of an oil emulsion or dispersion.

Please delete claim 46.